Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golcadomide - Celgene Corporation

Next Previous
Drug Profile

Golcadomide - Celgene Corporation

Alternative Names: A/I CELMoD; BMS-986369; CC-99282

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CRBN protein modulators; Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III B-cell lymphoma
  • Phase II Follicular lymphoma
  • Phase I/II Non-Hodgkin's lymphoma; T-cell lymphoma
  • Phase I Diffuse large B cell lymphoma
  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 12 Jun 2025 Efficacy and adverse events data from a phase I trial in Diffuse large B cell lymphoma released by Bristol-Myers Squibb
  • 12 Jun 2025 Efficacy and adverse events data from a phase II trial in Follicular lymphoma released by Bristol-Myers Squibb
  • 04 Apr 2025 Celgene plans a phase III trial for Follicular lymphoma (Second-line therapy or greater, Combination therapy) in Australia, Brazil, Canada, Chile, Finland, France, Germany, Greece, India, Italy, South Korea, the Netherlands, Poland, Saudi Arabia, Spain, Turkey, United Kingdom, USA (NCT06911502)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top